{
  "id": 165823,
  "name": "ILLUMINA, INC.",
  "slug": "illumina-inc",
  "state": "CA",
  "description": "Sequencing and array-based solutions for genetic research, clinical and applied markets",
  "totalSpending": 1560000,
  "filings": 26,
  "yearlySpending": [
    {
      "year": 2019,
      "income": 240000
    },
    {
      "year": 2020,
      "income": 180000
    },
    {
      "year": 2021,
      "income": 180000
    },
    {
      "year": 2022,
      "income": 240000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 240000
    },
    {
      "year": 2025,
      "income": 240000
    }
  ],
  "firms": [
    "AVENUE SOLUTIONS"
  ],
  "lobbyists": [
    "TRACY SPICER",
    "ELIZABETH BARNETT",
    "JORDAN LACROSSE",
    "AMY TEJRAL"
  ],
  "issues": [
    "MMM",
    "MED",
    "BUD",
    "HCR",
    "VET",
    "LBR",
    null,
    "HOM"
  ],
  "sampleDescriptions": [
    "Issues related to the genetic sequencing industry and the use of genetic information in research and clinical settings.",
    "Issues related to genetic sequencing industry and the use of genetic information in research and clinical settings; \n\nDiscussions around reintroduction of H.R. 5062, Advancing Access to Precision Medicine Act from 115th Congress",
    "Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services",
    "National Institutes of Health (NIH) funding",
    "Issues related to genetic sequencing industry and the use of genetic information in research and clinical settings;",
    "Policies impacting Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services;\n\nH.R. 4144, Ending the Diagnostic Odyssey Act of 2019",
    "National Institutes of Health (NIH) funding/All of Me program",
    "H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement. H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;    \n\nPublic Law 116-136 - CARES Act;\n\nPublic Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act;\n\nH.R.6800, The Heroes Act; \n\nCDC surveillance funding",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;\n\nH.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;    \n\nPublic Law 116-136 - CARES Act;\n\nPublic Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act;\n\nH.R. 6800, The Heroes Act; \n\nH.R. 925, The Heroes Act;\n\nCDC surveillance funding;\n\nCURES 2.0 discussion draft",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;\n\nH.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;    \n\nPublic Law 116-136 - CARES Act;\n\nPublic Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act;\n\nH.R. 6800, The Heroes Act; \n\nH.R. 925, The Heroes Act;\n\nCDC surveillance funding;\n\nCURES 2.0 discussion draft;\n\nH.R. 133/P.L. 116-260, Consolidated Appropriations Act, 2021",
    "Million Veterans Program (MVP) - issues related to precision medicine",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; \n\nS. 2022, Ending the Diagnostic Odyssey Act;  \n\nCURES 2.0 Discussion Draft;  \n\nImplementation of PL 117-2, American Rescue Plan Act of 2021;   \n\nContinued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); \n \nOngoing monitoring of CDC surveillance funding;  \n\nMonitor S. 1260, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;  \n\nH.R.791/S.236, Tracking COVID-19 Variants Act",
    "Issues related to FTC, mergers, antitrust",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; \n\nS. 2022, Ending the Diagnostic Odyssey Act;  \n\nCURES 2.0 Discussion Draft;  \n\nImplementation of PL 117-2, American Rescue Plan Act of 2021;   \n\nContinued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); \n \nOngoing monitoring of CDC surveillance funding;  \n\nMonitor S. 1260, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;  \n\nH.R.791/S.236, Tracking COVID-19 Variants Act;\n\nH.R. 5376, Build Back Better Act",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;  \n\nS. 2022, Ending the Diagnostic Odyssey Act;  \n\nCURES 2.0 Discussion Draft;  \n\nImplementation of PL 117-2, American Rescue Plan Act of 2021;   \n\nContinued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); \n \nOngoing monitoring of CDC surveillance funding;  \n\nMonitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors; \n\nMonitor H.R. 2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;  \n\nH.R.791/S.236, Tracking COVID-19 Variants Act;\n\nH.R. 5376, Build Back Better Act",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Implementation of American Rescue Plan Act of 2021 (PL 117-2); Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); Ongoing monitoring of CDC surveillance funding; Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R. 2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R. 4521, America COMPETES Act of 2022 and efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act; H.R. 5376, Build Back Better Act; H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 Presidents Budget S.3534/H.R.7152, Tracking Pathogens Act",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Ongoing monitoring of CDC surveillance funding; Monitor Conference negotiations between H.R. 4521, America COMPETES Act of 2022 and S. 1260, United States Innovation and Competition Act of 2021 and their efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act; H.R. 5376, Build Back Better Act; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 Presidents Budget S.3534/H.R.7152, Tracking Pathogens Act",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Ongoing monitoring of CDC surveillance funding; Chips and Science Act (PL 117-167); H.R. 791/S. 236, Tracking COVID-19 Variants Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 President's Budget; S.3534/H.R.7152, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act",
    "Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; Issues to related to Biotechnology and Biosecurity best practices; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; H.R. 791/S. 236, Tracking COVID-19 Variants Act; S.3534/H.R.7152, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act H. Rpt. 107-443, Explanatory Statement accompanying Division H - Departments of Labor, Health and Human Services, and Education, and related Agencies Appropriations Act, 2023 - related to whole genome sequencing"
  ],
  "years": [
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 0,
  "trajectory": "stable",
  "yearsActive": 7,
  "avgAnnualSpending": 222857,
  "peakYear": 2019,
  "lobbyistCount": 4,
  "firmCount": 1,
  "issueCount": 7
}